ImmunoGen, Inc. Announces Webcast of Panel Session at the 2006 RBC Capital Markets Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 6, 2006--ImmunoGen, Inc. (Nasdaq: IMGN) today announced that Mitchel Sayare, Chairman and CEO of the Company, will participate on the panel, Cancer Antibodies: Developing a Pipeline, at the 2006 RBC Capital Markets Healthcare Conference. This 55-minute panel session will begin at 11:00 a.m. EST on December 13, 2006, and will be webcast live. The Conference will take place at the Westin New York at Times Square hotel in New York City.
The webcast can be accessed through the "Investor Relations" section of the ImmunoGen website, http://www.immunogen.com. Following the live webcast, a replay of the panel discussion will be available at the same location until December 20, 2006.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer biopharmaceuticals. The Company's proprietary Tumor-Activated Prodrug (TAP) technology uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells. Five anticancer compounds are in clinical testing through ImmunoGen and the Company's collaborators - huN901-DM1 and huC242-DM4, which are wholly owned by ImmunoGen, AVE9633 and AVE1642, in development by sanofi-aventis, and trastuzumab-DM1, in development by Genentech. Amgen (formerly Abgenix), Biogen Idec, Biotest AG, Boehringer Ingelheim, Centocor (Johnson & Johnson), Genentech, Millennium Pharmaceuticals, Inc., and sanofi-aventis have licensed the right to develop and/or test TAP compounds to specific targets; ImmunoGen also has a broader collaboration with sanofi-aventis.
CONTACT:
Investors
ImmunoGen, Inc.
Carol Hausner, 617-995-2500
Executive Director, Investor Relations and Corporate Communications
info@immunogen.com
SOURCE:
ImmunoGen, Inc.
